<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16730">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035709</url>
  </required_header>
  <id_info>
    <org_study_id>TCI-PCA-001</org_study_id>
    <secondary_id>2013-002875-16</secondary_id>
    <nct_id>NCT02035709</nct_id>
  </id_info>
  <brief_title>Postoperative Pain Therapy With Hydromorphone Using TCI-PCA</brief_title>
  <acronym>TCI-PCA</acronym>
  <official_title>Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) After Elective Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of postoperative pain with hydromorphone (a strong analgesic) using
      patient-controlled analgesia with target concentrations in blood compared to conventional
      patient-controlled analgesia after planed cardiac surgery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hydromorphone Plasma Concentrations</measure>
    <time_frame>Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour  for the following 17 hours after extubation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Predictive accuracy of the &quot;Erlanger pharmacokinetic model&quot; of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Score</measure>
    <time_frame>Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour  for the following 17 hours after extubation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding analgetic efficiency</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Amount of Hydromorphone Administered</measure>
    <time_frame>Day 1 (Visit 3 on first day after surgery)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding the amount of hydromorphone administered</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>TCI-PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Patient-Controlled Analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.</description>
    <arm_group_label>TCI-PCA</arm_group_label>
    <arm_group_label>PCA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age between 40 and 85 years, both genders

          -  Scheduled for elective cardiac surgery involving thoracotomy and subsequent ICU stay

        Exclusion Criteria:

          -  Administration of other analgesics or sedatives, if not administered in stable dosage
             for at least 14 days or if not used for premedication and surgery

          -  Administration of hydromorphone in the period between screening and surgery

          -  Severe hepatic or renal impairment in medical history

          -  BMI ≥35 kg/m²

          -  ASA ≥4
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jeleazcov, MD, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Jeleazcov, MD, Associate Professor</last_name>
    <phone>+49 9131 8533901</phone>
    <email>christian.jeleazcov@kfa.imed.uni-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Jeleazcov, MD, Associate Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesiology, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Jeleazcov, MD</last_name>
      <phone>00499131853</phone>
      <phone_ext>3901</phone_ext>
      <email>christian.jeleazcov@kfa.imed.uni-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Jeleazcov, MD, Associate Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jeleazcov C, Saari TI, Ihmsen H, Mell J, Fröhlich K, Krajinovic L, Fechner J, Schüttler J. Population Pharmacokinetic Modeling of Hydromorphone in Cardiac Surgery Patients during Postoperative Pain Therapy. Anesthesiology. 2013 Aug 16. [Epub ahead of print]</citation>
    <PMID>23958818</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
